Clinuvel Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 10/3/2026)
| Balance Sheet | Total Assets | 178,765,824.88 | ROE | 92.47 % |
| Balance Sheet | Total Equity | 165,311,080.66 | ROA | 11.49 % |
| Cashflow | Capital Expenditures | -970,452.25 | P/FCF | 11.39 |
| Cashflow | Free Cash Flow | 20,494,277.75 | – | – |
| Cashflow | Operating Cash Flow | 21,464,730.00 | P/CF | 10.88 |
| Income | Earnings per Share (diluted) | 0.41 | Div. Yield | 0.65 % |
| Income | Net Income | 20,546,758.26 | P/E | 11.29 |
| Income | Shares Outstanding | 50,427,898.00 | P/B | 1.41 |
| Income | Total Revenue | 56,959,839.78 | P/S | 4.10 |
Ratios calculated on: 10/14/2026
Company Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.clinuvel.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more